ReviewTrends open2026
T cells are blind to the dark mechanics of tumors.
Review in Trends open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor mechanics differ profoundly from those of healthy tissues. Yet, how abnormal mechanical properties affect T cell activation remains largely unresolved. In this opinion article, we propose that the aberrant mechanical landscape of cancer cells directly undermines early T cell activation. Substantiated by theory, we demonstrate that the lifetime of the T cell receptor-antigen bond critically depends on target cell elasticity and viscosity. By altering their viscoelastic properties, cancer cells can escape the mechanosensitive window required for T cell signaling, rendering themselves immunologically invisible. We term this phenomenon 'dark mechanics', a process where tumors exploit physical traits to subvert antigen discrimination, creating a mechanical route of immune evasion. This discussion suggests an opportunity to mechanically illuminate tumors for next-generation immunotherapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.